Open Access Open Access  Restricted Access Subscription Access

In Indispensible Parameters of Pitavastatin Include Symptoms, Mechanism of Action, Administration, Adverse Effect, Contraindications, Toxicity and Enhancing Health Care Team Outcomes

Muralinath E., Madhavi Latha C., Ramadevi Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka. U., Sony Sharlet E.

Abstract


Pitavastatin is a medication used to treat and control hypercholesterolemia and dyslipidemia. It is a member of the class of drugs called statins. The action, indications, and contraindications of pitavastatin as a helpful drug for the treatment of dyslipidemia are explained in this activity. The mechanism of action, adverse event profile, dosage, pharmacokinetics, monitoring, and relevant interactions will be highlighted in this session to assist interprofessional team members in managing patients with dyslipidemia and related disorders.


Full Text:

PDF

References


Hoy, S. M. (2017). Pitavastatin: A review in hypercholesterolemia. American Journal of Cardiovascular Drugs, 17(2), 157–168.

Chan, P., Shao, L., Tomlinson, B., Zhang, Y., & Liu, Z. M. (2019). An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opinion on Pharmacotherapy, 20(1), 103–113.

Pirillo, A., & Catapano, A. L. (2017). Pitavastatin and HDL: Effects on plasma levels and function(s). Atherosclerosis Supplements, 27, e1–e9.

Benekos, T., Kosmeri, C., Vlahos, A., & Milionis, H. (2020). Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: A university hospital outpatient lipid clinic project in Northwestern Greece. Journal of Pediatric Endocrinology and Metabolism, 33(4), 533–538.

Braamskamp, M. J., Stefanutti, C., Langslet, G., Drogari, E., Wiegman, A., Hounslow, N., & Kastelein, J. J. (2015). Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. The Journal of Pediatrics, 167(2), 338–343.e5.

Mukhtar, R. Y., Reid, J., & Reckless, J. P. (2005). Pitavastatin. International Journal of Clinical Practice, 59(2), 239–252.

Kajinami, K., Takekoshi, N., & Saito, Y. (2003). Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovascular Drug Reviews, 21(3), 199–215.

Betteridge, J. (2010). Pitavastatin—Results from phase III & IV. Atherosclerosis Supplements, 11(3), 8–14.

Chamberlin, K. W., & Baker, W. L. (2015). Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clinical Interventions in Aging, 10, 733–740.

National Institute of Diabetes and Digestive and Kidney Diseases. (2021, December 1). Pitavastatin. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: Author.

Flores, N. A. (2002). Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo. Current Opinion in Investigational Drugs, 3(9), 1334–1341.

Teramoto, T. (2011). Pitavastatin: Clinical effects from the LIVES Study. Atherosclerosis Supplements, 12(3), 285–288.

Eiland, L. S., & Luttrell, P. K. (2010). Use of statins for dyslipidemia in the pediatric population. Journal of Pediatric Pharmacology and Therapeutics, 15(3), 160–172.

Brookhart, M. A., Patrick, A. R., Schneeweiss, S., Avorn, J., Dormuth, C., Shrank, W., van Wijk, B. L., Cadarette, S. M., Canning, C. F., & Solomon, D. H. (2007). Physician follow-up and provider continuity are associated with long-term medication adherence: A study of the dynamics of statin use. Archives of Internal Medicine, 167(8), 847–852.

Jelinek, M., Vale, M. J., Liew, D., Grigg, L., Dart, A., Hare, D. L., & Best, J. D. (2009). The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications: Two years follow-up. Heart, Lung and Circulation, 18(6), 388–392.


Refbacks

  • There are currently no refbacks.